Document Detail

Technologies for enhanced efficacy of DNA vaccines.
MedLine Citation:
PMID:  22309668     Owner:  NLM     Status:  MEDLINE    
Despite many years of research, human DNA vaccines have yet to fulfill their early promise. Over the past 15 years, multiple generations of DNA vaccines have been developed and tested in preclinical models for prophylactic and therapeutic applications in the areas of infectious disease and cancer, but have failed in the clinic. Thus, while DNA vaccines have achieved successful licensure for veterinary applications, their poor immunogenicity in humans when compared with traditional protein-based vaccines has hindered their progress. Many strategies have been attempted to improve DNA vaccine potency including use of more efficient promoters and codon optimization, addition of traditional or genetic adjuvants, electroporation, intradermal delivery and various prime-boost strategies. This review summarizes these advances in DNA vaccine technologies and attempts to answer the question of when DNA vaccines might eventually be licensed for human use.
Fadi Saade; Nikolai Petrovsky
Related Documents :
22500138 - Issues related to recent dengue vaccine development.
24125308 - Evolutionary vaccination dilemma in complex networks.
22894958 - Immunogenicity and safety of recombinant tetravalent dengue vaccine (cyd-tdv) in indivi...
22912938 - Development of capsular polysaccharide-based glycoconjugates for immunization against m...
8923398 - Improving pneumococcal vaccination rates in an elderly population by patient education ...
6497138 - Immunogenicity and safety of an attenuated bordetella bronchiseptica vaccine in pigs.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Review    
Journal Detail:
Title:  Expert review of vaccines     Volume:  11     ISSN:  1744-8395     ISO Abbreviation:  Expert Rev Vaccines     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-02-07     Completed Date:  2012-06-05     Revised Date:  2014-09-24    
Medline Journal Info:
Nlm Unique ID:  101155475     Medline TA:  Expert Rev Vaccines     Country:  England    
Other Details:
Languages:  eng     Pagination:  189-209     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adjuvants, Immunologic / administration & dosage,  adverse effects
Cancer Vaccines* / administration & dosage,  adverse effects,  genetics,  immunology
Clinical Trials as Topic
Communicable Diseases / immunology*
Cytokines / genetics,  immunology
Electroporation / methods
Guinea Pigs
Neoplasms / immunology,  therapy
Treatment Outcome
Vaccines, DNA* / administration & dosage,  adverse effects,  genetics,  immunology
Grant Support
HHSN272200800039C/AI/NIAID NIH HHS; HHSN272200800039C//PHS HHS; U01 AI061142/AI/NIAID NIH HHS; U01 AI061142/AI/NIAID NIH HHS; U01 AI061142-05/AI/NIAID NIH HHS
Reg. No./Substance:
0/Adjuvants, Immunologic; 0/Cancer Vaccines; 0/Cytokines; 0/Vaccines, DNA

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis seroco...
Next Document:  Remaining issues and challenges for rotavirus vaccine in preventing global childhood diarrheal morbi...